Bispecific therapy – treatment setting and management of short-term adverse events

Video content above is prompted by the following:

In patients treated with bispecific antibodies, what safety data are concerning to you?

What treatment guidelines do you have in place for CRS and ICANS and are they different for bispecifics vs CAR T cell?

Please comment on the use of dexamethasone as premedication to mitigate the occurrence of CRS. (Falchi L et al. 2023 ASH Annual Meeting. Abstract 3130.)

What is the clinical significance of prophylactic tocilizumab in managing CRS for bispecifics such as teclistamab? (van de Donk N et al. 2023 ASCO Annual Meeting. Abstract 8033.)